Med Ink Consulting

Med Ink Consulting provides medical communications services to pharmaceutical and biotechnology companies. The firm is led by Stephanie M. Vargas, MD, and Abigale Miller, MSc, offering expertise across multiple therapeutic areas including oncology, rare diseases, and autoimmune conditions.

The company delivers foundational medical communications materials such as scientific platforms, promotional medical education content including slide decks and e-learning modules, and full-service meeting support for advisory boards and workshops. Their approach emphasizes staying current with healthcare developments while maintaining patient advocacy at the core of their work. They also provide landscape assessments and engagement plans for patient advocacy and external affairs teams.

Med Ink Consulting has experience across eight therapeutic area categories, including hematologic malignancies, solid tumors, cardiovascular diseases, respiratory diseases, infectious diseases, bleeding disorders, autoimmune diseases, and rare diseases. The team provides both short- and long-term medical and scientific director support for client projects.

Consider Med Ink Consulting when you need medical communications expertise led by clinicians with therapeutic area depth, particularly in oncology or rare diseases. The firm's physician-led approach may appeal to companies seeking medical oversight for scientific accuracy and strategic alignment with clinical realities.

Expect a consultative engagement model focused on understanding client values and objectives before execution. Their meeting management and patient advocacy services suggest strength in stakeholder engagement and external-facing medical communications initiatives.

Med Ink Consulting operates exclusively in the pharmaceutical and biotechnology sectors, with all services designed for drug and medical product developers. Their healthcare focus centers on the intersection of clinical science, medical communications, and patient advocacy within life sciences companies. They demonstrate specific therapeutic area knowledge in hematologic malignancies, solid tumors, rare diseases, autoimmune diseases, cardiovascular diseases, infectious diseases, respiratory diseases, and bleeding disorders.

Pharmaceutical and biotechnology companies with products in oncology, rare diseases, autoimmune conditions, or other complex therapeutic areas requiring medical director-level expertise. Companies seeking to build foundational scientific platforms or develop patient advocacy strategies will find aligned capabilities. Both established brands and emerging therapies appear to fit their service model.